国邦医药 - Financials

国邦医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
+Revenue	5.9B	5.3B	5.7B	4.5B	4.2B	3.8B	3.3B	2.9B
Revenue Growth %	10.1%	-6.5%	27.0%	7.1%	10.6%	15.9%	12.9%	--
Total Revenue	5.9B	5.3B	5.7B	4.5B	4.2B	3.8B	3.3B	2.9B
Cost Of Revenue	4.4B	4.1B	4.1B	3.1B	2.8B	2.8B	2.3B	2.1B
+Gross Profit	1.5B	1.3B	1.6B	1.4B	1.4B	986.0M	975.0M	841.0M
Gross Margin %	25.0%	23.4%	27.5%	30.1%	34.0%	25.9%	29.7%	29.0%
Total Operating Cost	5.0B	4.7B	4.7B	3.7B	3.3B	3.2B	2.7B	2.4B
Selling Expenses	79.5M	74.2M	64.2M	55.9M	54.5M	76.7M	70.8M	61.5M
Admin Expenses	278.0M	303.0M	293.0M	254.0M	196.0M	176.0M	162.0M	140.0M
Rd Expenses	215.0M	191.0M	198.0M	155.0M	137.0M	124.0M	103.0M	94.7M
Finance Expenses	-29.8M	-46.3M	-68.0M	28.1M	81.8M	20.4M	-7.8M	45.1M
+Operating Income	895.0M	702.0M	1.1B	809.0M	936.0M	582.0M	580.0M	469.0M
Operating Margin %	15.2%	13.1%	18.4%	18.0%	22.3%	15.3%	17.7%	16.1%
Non Operating Income	3.7M	3.3M	562,600	9.7M	18.7M	2.3M	739,600	977,000
Non Operating Expenses	10.8M	7.9M	17.8M	11.7M	11.4M	7.9M	18.6M	17.4M
Investment Income	12.9M	13.2M	19.5M	4.3M	3.3M	10.5M	6.7M	6.9M
Fair Value Change Income	14.4M	10.3M	4.6M	6.3M	34,800	2.2M	--	-90,500
Asset Disposal Income	-9.1M	--	45.00	301,900	-1.5M	26,100	603,900	370,000
Asset Impairment Loss	25.8M	31.4M	27.7M	51.8M	14.4M	16.1M	56.4M	20.0M
Other Income	31.2M	10.8M	12.8M	10.7M	11.4M	8.4M	5.5M	2.9M
Income Before Tax	888.0M	698.0M	1.0B	807.0M	943.0M	576.0M	562.0M	453.0M
Income Tax	107.0M	87.7M	115.0M	101.0M	133.0M	81.9M	78.4M	61.7M
+Net Income	781.0M	610.0M	921.0M	706.0M	810.0M	494.0M	483.0M	391.0M
Net Margin %	13.3%	11.4%	16.1%	15.7%	19.3%	13.0%	14.7%	13.5%
Net Income Attributable	782.0M	612.0M	921.0M	706.0M	810.0M	315.0M	211.0M	178.0M
Minority Interest	-1.0M	-2.5M	-282,200	199,200	288,300	179.0M	273.0M	214.0M
Eps Basic	1.40	1.10	1.65	1.38	1.71	0.66	--	--
Eps Diluted	1.40	1.10	1.65	1.38	1.71	0.66	--	--

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash And Equivalents	1.9B	2.1B	2.0B	893.0M	1.2B	1.1B	1.0B	946.0M
Trading Financial Assets	618.0M	466.0M	825.0M	1.3B	34,800	150.0M	--	--
Accounts Receivable	754.0M	532.0M	667.0M	445.0M	385.0M	377.0M	364.0M	383.0M
Notes Receivable	--	--	--	--	--	--	152.0M	165.0M
Notes And Accounts Receivable	754.0M	532.0M	667.0M	445.0M	385.0M	377.0M	515.0M	548.0M
Prepayments	584.0M	477.0M	39.2M	450.0M	42.8M	50.7M	8.8M	22.4M
Inventory	1.4B	1.4B	1.4B	1.3B	990.0M	847.0M	869.0M	616.0M
Total Current Assets	5.9B	5.4B	5.1B	4.6B	2.9B	2.8B	2.8B	2.4B
Long Term Equity Investment	103.0M	101.0M	101.0M	17.1M	18.7M	20.0M	--	--
Fixed Assets	--	3.7B	2.4B	1.8B	1.6B	1.2B	1.0B	--
Fixed Assets Total	4.1B	3.7B	2.4B	1.8B	1.6B	1.2B	1.0B	949.0M
Construction In Progress	--	636.0M	860.0M	787.0M	568.0M	276.0M	140.0M	--
Construction In Progress Total	255.0M	637.0M	875.0M	827.0M	571.0M	278.0M	146.0M	164.0M
Intangible Assets	351.0M	359.0M	370.0M	272.0M	267.0M	275.0M	156.0M	130.0M
Long Term Deferred Expenses	7.4M	8.0M	9.3M	2.6M	3.4M	2.2M	1.5M	1.9M
Total Non Current Assets	4.9B	4.9B	3.9B	2.9B	2.6B	2.0B	1.5B	1.6B
Total Assets	10.8B	10.4B	9.0B	7.5B	5.5B	4.8B	4.4B	4.0B
Short Term Borrowings	175.0M	483.0M	656.0M	160.0M	509.0M	348.0M	553.0M	655.0M
Accounts Payable	492.0M	624.0M	432.0M	357.0M	441.0M	433.0M	321.0M	296.0M
Advance Receipts	--	--	--	--	--	35.0M	21.2M	27.6M
Contract Liabilities	39.9M	55.8M	52.8M	30.7M	42.7M	--	--	--
Total Current Liabilities	2.6B	2.5B	1.9B	1.2B	2.0B	1.6B	1.7B	1.8B
Long Term Borrowings	147.0M	452.0M	--	--	251.0M	483.0M	27.0M	--
Total Non Current Liabilities	171.0M	475.0M	26.2M	13.9M	262.0M	570.0M	58.6M	4.9M
Total Liabilities	2.7B	2.9B	1.9B	1.2B	2.2B	2.1B	1.8B	1.8B
Paid In Capital	559.0M	559.0M	559.0M	559.0M	475.0M	475.0M	76.0M	76.0M
Capital Reserve	3.6B	3.6B	3.6B	3.6B	1.0B	1.0B	20.7M	22.2M
Surplus Reserve	213.0M	184.0M	142.0M	125.0M	25.2M	20.0M	49.9M	44.9M
Retained Earnings	3.7B	3.1B	2.8B	2.1B	1.7B	1.1B	1.1B	936.0M
Minority Equity	4.7M	5.2M	-651,100	-385,700	-585,000	-873,300	1.3B	1.1B
Equity Attributable	8.0B	7.4B	7.2B	6.3B	3.3B	2.6B	1.2B	1.1B
Total Equity	8.1B	7.4B	7.2B	6.3B	3.3B	2.6B	2.6B	2.2B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash From Sales	4.3B	2.9B	2.8B	2.7B	2.5B	2.1B	1.9B	1.4B
Tax Refunds Received	132.0M	200.0M	201.0M	137.0M	156.0M	111.0M	111.0M	95.6M
Total Operating Cash Inflow	4.6B	3.2B	3.1B	2.9B	2.7B	2.3B	2.1B	1.5B
Cash Paid For Goods	2.7B	1.7B	1.0B	2.2B	1.2B	1.1B	871.0M	835.0M
Cash Paid To Employees	578.0M	580.0M	505.0M	426.0M	340.0M	290.0M	275.0M	212.0M
Taxes Paid	180.0M	99.2M	232.0M	173.0M	191.0M	208.0M	165.0M	144.0M
Total Operating Cash Outflow	3.9B	2.7B	2.1B	3.0B	1.9B	1.8B	1.5B	1.4B
Operating Cash Flow	706.0M	517.0M	1.0B	-176.0M	768.0M	441.0M	542.0M	148.0M
Total Investing Cash Inflow	5.3B	1.4B	3.5B	1.8B	577.0M	1.6B	835.0M	579.0M
Total Investing Cash Outflow	5.8B	1.7B	4.0B	3.5B	942.0M	1.9B	981.0M	657.0M
Investing Cash Flow	-514.0M	-361.0M	-412.0M	-1.7B	-365.0M	-307.0M	-146.0M	-77.2M
Cash From Borrowings	593.0M	964.0M	778.0M	364.0M	552.0M	1.2B	789.0M	782.0M
Dividends And Interest Paid	194.0M	362.0M	128.0M	334.0M	205.0M	181.0M	88.0M	61.0M
Debt Repayments	782.0M	657.0M	283.0M	1.1B	472.0M	1.0B	891.0M	793.0M
Total Financing Cash Inflow	691.0M	973.0M	779.0M	3.0B	555.0M	1.9B	840.0M	782.0M
Total Financing Cash Outflow	1.1B	1.0B	412.0M	1.5B	829.0M	1.9B	1.1B	880.0M
Financing Cash Flow	-386.0M	-45.9M	367.0M	1.6B	-274.0M	-47.0M	-214.0M	-97.8M
Net Change In Cash	-167.0M	120.0M	1.0B	-305.0M	96.0M	91.9M	190.0M	-44.1M
Ending Cash Balance	1.5B	1.7B	1.6B	574.0M	879.0M	783.0M	691.0M	502.0M
Capex	419.0M	748.0M	803.0M	448.0M	520.0M	605.0M	163.0M	169.0M